InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $3.600 0.81 (29.03%)+
Announcement
Release
18 Aug 2026 8:19AM
Price at Release
$2.790
Full Release
download
Summary
Cogstate Limited reported significant growth in FY26 with a 15% increase in revenue, reaching $60.9 million, and a 16% rise in Profit Before Tax to $16.1 million. The company achieved a 58% Gross Profit margin and successfully expanded its project base with 90 new clinical trial starts. Looking forward to FY27, Cogstate has a strong revenue base with $48.3 million expected to be recognized and plans to invest in AI-enabled platforms to enhance scalability and efficiency in CNS trials. The company's positive financial outlook is further reflected in an increased dividend payout.
Key Points
  • Cogstate Ltd achieved record sales, revenue, and profit in FY26 while maintaining disciplined investment.
  • Revenue for FY26 stood at $60.9 million, marking a 15% increase from FY25.
  • The company reported a 16% increase in Profit Before Tax, reaching $16.1 million.
  • Gross Profit margin was 58% with a notable margin expansion in the second half of FY26.
  • FY27 starts with a strong base of committed revenue, with $48.3 million expected to be recognized.
  • Cogstate's clinical trials saw a record number of 90 new trial starts in FY26, providing a broader and deeper project base.
  • The company is focusing on AI-enabled platforms for CNS trials to enhance operational efficiency and scalability over FY27 and FY28.
  • Cogstate declared a dividend of A$0.04 per share, fully franked, reflecting confidence in growth prospects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.